-

Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Vanda Pharmaceuticals Inc. (VNDA)

SAN DIEGO & WASHINGTON--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) for breaches of fiduciary duties, unjust enrichment, and violations of the Securities Exchange Act of 1934. Vanda Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of central nervous system disorders.

If you suffered a loss as a result of Vanda's misconduct, click here.

Vanda Pharmaceuticals Used its Drugs for Off-Label Purposes

For years, Vanda and its officers hid that Vanda was involved in a fraudulent scheme that included violations of federal Medicare, Medicaid, and Tricare programs and that Vanda's promotional materials were false and misleading, garnering scrutiny from the FDA. Specifically, Vanda schemed to promote its drugs Fanapt and Hetlioz for "off-label" uses in addition to other prohibited promotional strategies. Vanda's executives and officers knew about the prohibited promotional strategies and actively participated in the fraudulent activity. Vanda also issued misleading statements regard tradipitant's clinical trials with the FDA. When the truth was revealed, Vanda's stock declined over 5% and has slipped even more, now trading at just around $11.00. As a result of this conduct, Vanda is facing significant liability from a Qui Tam lawsuit and has already incurred substantial expenses in its investigation. Vanda has also been named as a defendant in a securities class action lawsuit, causing further damage to the company.

Vanda Pharmaceuticals Inc. (VNDA) Shareholders Have Legal Options

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. For be notified if a class action against Vanda Pharmaceuticals settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Vistagen Therapeutics, Inc. Securities Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024 and December 16, 2025. Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. For more information, submit a form, email attorney Aaron Dumas...

Investor Notice: Robbins LLP Informs Investors of the Securities Class Action Against Oracle Corporation

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that a class action was filed on behalf of all persons and/or entities who purchased or otherwise acquired Oracle Corporation (NYSE: ORCL) Senior Notes issued pursuant to the Shelf Registration Statement filed with the SEC on March 15, 2024, and as supplemented on September 25, 2025. Oracle is an Austin, Texas-based company that sells database software, enterprise applications, and cloud infrastructure and hardware. For more information,...

Investor Notice: Robbins LLP Informs Investors of the Smart Digital Group Limited Securities Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Smart Digital Group Limited (NASDAQ: SDM) securities between May 5, 2025 and September 26, 2025. Smart Digital, together with its subsidiaries, provides internet media, business planning and consulting, event planning and execution, and software customization and marketing services in Mainland China and Macau. For more information, submit a fo...
Back to Newsroom